MiNK Therapeutics, Inc. INKT
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
MiNK Therapeutics, Inc. (INKT) is a healthcare company listed in the US with a market value of about $48M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -94%.
About MiNK Therapeutics
MiNK Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 27% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- ROE above 15%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$12M | -$11M | -$22M | -$28M | -$30M | -$16M |
| Free cash flow | — | — | -$16M | -$19M | -$13M | -$8M |
| EPS (diluted) | $-2.93 | $-2.86 | $-6.54 | $-8.30 | $-11.60 | $-6.70 |
| Net margin | — | — | — | — | — | — |
| ROIC | — | — | — | — | -94.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $44.00, 371% above the current price; targets range from $38.00 to $50.00; the consensus rating is “Strong buy”; expected EPS is $-2.45 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does MiNK Therapeutics pay a dividend?
Not currently.
Is MiNK Therapeutics a good stock to buy?
We do not give buy or sell advice. MiNK Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.